- Rapid reduction in disease activity seen at 12 weeks was sustained at one year
- 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared
- Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress
Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.